stockrowAstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +22.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
Follow AZN
Alert me
AstraZeneca PLC (AZN) EBITDA
AstraZeneca PLC's EBITDA for fiscal 2025 was $19.5B, up 16.7% from $16.7B in fiscal 2024. Over the twelve months to 30 September 2026 it was $21.2B. Over the past ten years it has ranged from $6.7B (fiscal 2019) to $19.5B (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 4 consecutive fiscal years. AstraZeneca PLC ranks 6th of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $19.5B | 16.69% |
| FY2024 | $16.7B | 22.91% |
| FY2023 | $13.6B | 47.02% |
| FY2022 | $9.2B | 21.76% |
| FY2021 | $7.6B | (8.72%) |
| FY2020 | $8.3B | 24.30% |
| FY2019 | $6.7B | (6.36%) |
| FY2018 | $7.1B | 6.36% |
| FY2017 | $6.7B | (7.52%) |
| FY2016 | $7.3B | 4.21% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $6.0B | 17.65% |
| Jun 2026 | $5.1B | (9.25%) |
| Mar 2026 | $5.6B | 25.02% |
| Dec 2025 | $4.5B | (12.53%) |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ABBV AbbVie Inc. compare | $28.9B |
| NVO Novo Nordisk A/S compare | $26.5B |
| NVS Novartis AG compare | $22.1B |
| AZN AstraZeneca PLC | $21.2B |
| PFE Pfizer Inc. compare | $20.1B |
| AMGN Amgen Inc. compare | $16.5B |
| BMY Bristol Myers Squibb Company compare | $14.1B |
| MRK Merck & Co., Inc. compare | $13.7B |
| GILD Gilead Sciences, Inc. compare | $451.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on AZN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement